Dr Carl Anderson
Carl is the Interim Head of the Human Genetics Programme and a Senior Group Leader at the Wellcome Sanger Institute, where he leads the Genomics of Inflammation and Immunity Group.
His research primarily focuses on using genetic and genomic data to understand complex disease susceptibility, progression and drug response, with a particular focus on inflammatory bowel disease. Carl is co-Chief Investigator and Scientific Lead for Open-IBD
.png)
Dr Cristina Cotobal
Cristina is a Senior Staff Scientist in the Genomics of Inflammation and Immunity group at the Wellcome Sanger Institute. Cristina leads the experimental team in Carl Anderson’s group.
Cristina’s work applies single cell omics techniques on human samples to generate large-scale genetic and genomic data to elucidate biological mechanisms affecting immune mediated diseases, with a special interest in Inflammatory Bowel Disease.
Dr Laura Fachal
Laura is a Senior Staff Scientist at the Wellcome Sanger Institute.
Laura leads a large international collaborative effort, driven by the International IBD Consortium to identify new genetic variants, and genes, associated with IBD susceptibility in order to further increase our understanding of the biology of the disease, and to reveal new potential therapeutic targets.
Dr Michelle Strickland
Michelle is a Technical Specialist in the Genomics of Inflammation and Immunity group at the Wellcome Sanger Institute, led by Carl Anderson.
Michelle acts as a link between the Open IBD clinical teams and the Sanger laboratories, working closely with nurses, technicians and lab staff to facilitate sample logistics and sequencing. Michelle brings experience of large-scale projects including the IBD-Response project, and was instrumental in the project setup and sample processing as well as supporting the on boarding of project managers and supporting teams.
